Yellow Bonds convert philanthropic guarantees into revolving research capital. A $250M guarantee pool anchors a self-liquidating five-cycle issuance program, mobilizing more than $2 billion in research capital · without spending the guarantee.
The pediatric oncology funding ecosystem is structurally misaligned. Government budgets are constrained by voting populations. Philanthropic capital is fragmented across thousands of organizations. The market will not fund what children need. Three data points frame the failure.
Less than 4% of the National Cancer Institute's budget funds all childhood cancers combined.1 Fewer than ten drugs have been initially approved by the FDA specifically for a pediatric cancer indication.2 Adult cancers collectively receive more than 96% of NCI oncology research funding.
A 2019 JAMA Oncology analysis of 77 potential pediatric oncology projects found expected returns of approximately negative 24% on private-sector drug development.3 None could generate positive returns without philanthropic co-investment. Pediatric populations are too small to attract commercial capital without structural support.
The MAP regimen · methotrexate, doxorubicin, cisplatin · has been the backbone of osteosarcoma treatment since the 1980s.4 No new first-line agent has achieved FDA approval for osteosarcoma in over three decades. Five-year survival for metastatic osteosarcoma remains below 30%.5
Yellow Bonds borrow from proven blended finance frameworks. The structure applies the risk-layering and portfolio construction techniques of institutional credit markets to a domain that has relied on episodic, sub-scale philanthropic funding.
Yellow Bonds are self-liquidating. A philanthropic guarantee anchors the structure · bond proceeds fund a diversified research portfolio · portfolio revenues repay par at maturity · the guarantee rolls forward. Four mechanical steps, five cycles, every cycle larger than the last.
Philanthropic capital commits to the guarantee pool and sits in AAA U.S. Treasuries, earning yield. Capital is not disbursed · it serves as first-loss credit enhancement, called only if portfolio revenues fall short of par at maturity.
Bond proceeds deploy across a large portfolio of pediatric oncology research projects · diversified by disease subtype, development stage, therapeutic modality, and geography. Peer-reviewed, milestone-tranched, portfolio-governed.
The research portfolio generates revenue through royalty licensing, milestone payments, Priority Review Vouchers (worth $100-150M each), platform technology licensing, and therapeutic sales. Accumulated revenues are designed to repay par at maturity · without calling the guarantee.
The guarantee pool remains intact across cycles. As portfolio data seasons and governance matures, coverage requirements decline · 50% (Series A) to 30% (Series E). The same $250M backs progressively larger bonds, compounding deployment without new philanthropic capital.
Proceeds calculated at 4.5% yield on 10-year zero-coupon issuances with par totaling $3.23B across the five series. Treasury yield reflects ~4% on the $250M pool across the issuance horizon. Declining coverage is earned, not asserted · by Series C, the program has a decade of portfolio performance data, governance track record, and potentially a rating history that support tighter structural terms on each successive issuance.
Yellow Bonds are a novel combination of proven components. Each structural element has been validated at scale in adjacent domains.
Yellow Bonds convert philanthropic intent into institutional-grade capital deployment. The guarantee is a structural commitment, not a disbursement.
Across five cycles with declining coverage and Treasury yield on the pool, every dollar of guarantee underwrites approximately nine dollars of deployed research capital · a 9× multiplier. This leverage is not available through direct grantmaking.
The guarantee sits in AAA U.S. Treasuries, earning yield. It is a contingent liability, not a cash outlay · called only if portfolio revenues fall short. For foundations and DAFs, this is capital-efficient use of balance sheet assets.
The guarantee structure qualifies as a Program-Related Investment for private foundations · counting toward the 5% minimum distribution requirement while preserving principal. DAF sponsors can commit under mission-aligned investment policies.
Independent SPV trustee, Big 4 audit, quarterly reporting to all stakeholders, scientific advisory board governing portfolio construction. Guarantors hold board representation on the governing entity with full impact reporting.
Smaller commitments are welcomed alongside anchor capital. The structure accommodates a range of guarantor sizes · from anchor foundations and sovereigns to DAFs and family offices · provided the aggregate pool reaches target size.
Yellow Bonds are being developed at the intersection of structured finance and pediatric oncology research funding. The team is resourced to design, issue, and govern the instrument at institutional standards, supported by pediatric oncology clinicians and capital-markets counsel.
But Yellow Bonds are not a product. They are the beginning of a coalition · foundations, donor-advised funds, sovereigns, institutional investors, research institutions, clinicians, and patient advocates aligning around a new way to fund childhood cancer research at scale.
The goal is not a single bond. The goal is to fundamentally and sustainably change how childhood cancer research is financed · replacing episodic, fragmented grantmaking with a revolving institutional mechanism that matches the scale of the science and the duration of the need.
Yellow Bonds are in pre-issuance development. We are engaging potential guarantors and institutional investors on a structured basis. Submit your details and we will follow up with materials appropriate to your stakeholder type.